Chinese authorities included the dextromethorphan hydrochloride sustained-release capsules manufactured by China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Henan Zhongshuai Pharmaceutical in the country's national insurance drug catalog.
The drug is used as a psychostimulant for attention deficit hyperactivity disorder and nodular disorders in children aged 6 and above, according to a Tuesday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments